Finance

Lists
Outlook: 45.5% bullish·9.1% bearish
Go to analysis
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
$229.95
-1.17%
(-2.73) 1D
Oct 12, 11:08:42 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALNY...
Open
$233.13
High
$233.60
Low
$228.59
Mkt. cap
30.77B
Avg. vol.
1.49M
Volume
279.07K
P/E ratio
39.11
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.28
Shares outstanding
133.81M
No. of employees
2K
Open
$233.13
High
$233.60
Low
$228.59
Mkt. cap
30.77B
Avg. vol.
1.49M
Volume
279.07K
P/E ratio
39.11
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.28
Shares outstanding
133.81M
No. of employees
2K
News stories
From web sources and news partners
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.
CEO-
Employees2.5K
FoundedJun 14, 2002
Headquarters-
SectorBiotechnology
Websitealnylam.com
Analyst ratings
Based on 22 analysts giving stock ratings to ALNY in the past 3 months
Strong buy
Buy
18
Hold
4
Sell
0
12-month forecast
Based on 22 Wall Street analysts offering 12 month price targets for ALNY in the last 3 months.
Highest
Current $229.95
$489.00 (+112.65%)
Average
$366.54 (+59.40%)
Lowest
$256.00 (+11.33%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
-
-
10/09/2026
Michael Ulz
Morgan Stanley
Hold
Maintained
$300.00
+30.5%
10/09/2026
Luca Issi
RBC Capital
Buy
Maintained
$345.00
+50%
10/08/2026
Olivia Brayer
Cantor Fitzgerald
Hold
Maintained
$325.00
+41.3%
09/30/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
$369.00
+60.5%
09/30/2026
Jeffrey Walch
Bernstein
Buy
Maintained
$376.00
+63.5%
09/25/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$455.00
+97.9%
09/21/2026
David Lebowitz
BMO Capital
Buy
Maintained
$318.00
+38.3%
09/17/2026
Danielle Brill
Truist Financial
Buy
Reiterated
-
-
09/18/2026
Joseph Stringer
Needham
Buy
Maintained
$357.00
+55.3%
09/17/2026
Faisal Khurshid
Jefferies
Hold
Maintained
$260.00
+13.1%
09/08/2026
Eliana Merle
Barclays
Buy
Maintained
$450.00
+95.7%
09/01/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$325.20
+41.4%
08/31/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$489.00
+112.7%
08/31/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
$318.00
+38.3%
08/31/2026
Eric Joseph
Citi
Buy
Maintained
$340.00
+47.9%
08/31/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$429.00
+86.6%
08/28/2026
Unknown Analyst
BMO Capital
Buy
Initiated
$318.00
+38.3%
08/18/2026
Unknown Analyst
Wells Fargo
Hold
Reiterated
$256.00
+11.3%
08/14/2026
Martin Auster
Raymond James
Buy
Maintained
$420.00
+82.6%
07/31/2026
Kostas Biliouris
Oppenheimer
Buy
Maintained
$350.00
+52.2%
07/31/2026
Ritu Baral
TD Cowen
Buy
Reiterated
$482.00
+109.6%
07/31/2026
Myles Minter
William Blair
Buy
Maintained
-
-
07/30/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$550.00
+139.2%
06/25/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
$420.00
+82.6%
05/20/2026
Unknown Analyst
Citi
Buy
Initiated
$380.00
+65.3%
05/19/2026
William Pickering
Bernstein
Buy
Reiterated
$447.00
+94.4%
05/01/2026
Tiago Fauth
Raymond James
Hold
Maintained
$377.00
+63.9%
05/01/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
$425.00
+84.8%
05/01/2026
Last report
Jul 30, 2026
Fiscal period
Q2 2026
$1.84 / $2.14
-14.21%miss
Revenue / Est. (USD)
1.29B / 1.32B
-2.22%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.25B
1.10B
1.17B
1.29B
Cost of goods sold
200.15M
267.72M
211.12M
298.45M
Cost of revenue
200.15M
267.72M
211.12M
298.45M
Research and development expenses
358.81M
372.22M
364.87M
413.13M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
322.08M
325.37M
322.55M
347.92M
Operating expense
680.89M
697.59M
687.42M
761.06M
Total operating expenses
881.04M
965.32M
898.54M
1.06B
Operating income
367.98M
131.72M
268.64M
231.44M
Other non operating income
-74.15M
92.98M
-4.30M
273.00K
EBT including unusual items
238.97M
161.14M
221.65M
177.81M
EBT excluding unusual items
278.12M
121.99M
221.65M
177.81M
Income tax expense
-12.12M
-25.28M
15.66M
13.31M
Effective tax rate
-5.07%
-15.69%
7.07%
7.49%
Other operating expenses
-
-
-
-
Net income
251.08M
186.42M
205.99M
164.49M
Net profit margin
20.10%
16.99%
17.65%
12.74%
Earnings per share
2.90
1.25
1.99
1.84
Interest and investment income
28.68M
26.63M
26.60M
28.14M
Interest expense
-44.40M
-129.34M
-69.29M
-82.05M
Net interest expenses
-15.72M
-102.71M
-42.69M
-53.91M
Depreciation and amortization charges
-
-
-
-
EBITDA
381.78M
145.22M
282.19M
245.34M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps